The Food and Drug Administration (FDA) approved updated labelling for temozolomide under Project Renewal, an Oncology Center of Excellence (OCE) initiative aimed at updating labelling information for older oncology drugs to ensure information is clinically meaningful and scientifically up-to-date. This is the second drug to receive a labelling update under this pilot program. The first drug that received approval under Project Renewal was capecitabine.
Project Renewal is a collaborative program that leverages external oncology experts and early-career scientists to review existing published literature and gain first-hand experience in the selection, curation, and evaluation of evidence for independent FDA review. Project Renewal is intended to keep older, commonly prescribed oncology drugs’ labelling up-to-date while providing transparency on FDA’s evaluation process and evidentiary standards, and improving awareness of drug labelling as an information resource.
Temozolomide is now approved for the following new and revised indications:
One approved indication for temozolomide remains the same:
Additional labelling revisions include:
Project Renewal is limited to updating the labelling of older oncology drugs with decades of use, multiple supportive clinical studies, and substantial post-marketing experience. For information on the key studies supporting a new or revised indication, see temozolomide’s prescribing information.
View full prescribing information for temozolomide here.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.